Tevogen, Inc. (TVGN)
5.905
-0.24
(-3.83%)
USD |
NASDAQ |
Nov 19, 16:00
5.905
0.00 (0.00%)
After-Hours: 20:00
Tevogen Enterprise Value : 116.47M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 116.47M |
| November 17, 2026 | 109.39M |
| November 16, 2026 | 117.73M |
| November 13, 2026 | 114.27M |
| November 12, 2026 | 109.86M |
| November 11, 2026 | 114.27M |
| November 10, 2026 | 109.86M |
| November 09, 2026 | 111.75M |
| November 06, 2026 | 107.82M |
| November 05, 2026 | 107.34M |
| November 04, 2026 | 109.86M |
| November 03, 2026 | 113.01M |
| November 02, 2026 | 107.82M |
| October 30, 2026 | 112.69M |
| October 29, 2026 | 115.05M |
| October 28, 2026 | 118.04M |
| October 27, 2026 | 118.67M |
| October 26, 2026 | 118.20M |
| October 23, 2026 | 122.61M |
| October 22, 2026 | 127.01M |
| October 21, 2026 | 121.19M |
| October 20, 2026 | 127.17M |
| October 19, 2026 | 126.39M |
| October 16, 2026 | 131.11M |
| October 15, 2026 | 131.26M |
| Date | Value |
|---|---|
| October 14, 2026 | 122.22M |
| October 13, 2026 | 131.74M |
| October 12, 2026 | 124.95M |
| October 09, 2026 | 126.54M |
| October 08, 2026 | 130.95M |
| October 07, 2026 | 121.98M |
| October 06, 2026 | 121.98M |
| October 05, 2026 | 123.71M |
| October 02, 2026 | 129.69M |
| October 01, 2026 | 125.60M |
| September 30, 2026 | 124.02M |
| September 29, 2026 | 45.88M |
| September 28, 2026 | 45.93M |
| September 25, 2026 | 48.01M |
| September 24, 2026 | 50.56M |
| September 23, 2026 | 50.39M |
| September 22, 2026 | 50.39M |
| September 21, 2026 | 48.78M |
| September 18, 2026 | 50.39M |
| September 17, 2026 | 49.97M |
| September 16, 2026 | 50.35M |
| September 15, 2026 | 50.14M |
| September 14, 2026 | 49.12M |
| September 11, 2026 | 48.48M |
| September 10, 2026 | 48.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oncolytics Biotech, Inc. | 56.19M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.732B |
| Anixa Biosciences, Inc. | 78.76M |
| Vicapsys Life Sciences, Inc. | 16.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.004M |
| Total Expenses (Quarterly) | 7.004M |
| EPS Diluted (Quarterly) | -1.756 |
| Earnings Yield | -103.2% |
| Normalized Earnings Yield | -103.26 |